Variations in postoperative patient-reported outcomes (PROs) attributed to patients, surgeons, or surgical centers.

R Roshan Paudel (Dana-Farber Cancer Institute, Boston, MA) H Hajime Uno C Christine M. Cronin (Dana-Farber Cancer Institute, Boston, MA) J Jessica J. Bian (Maine Medical Center, Portland, ME) E Eleonore Kugener (Brigham and Women's Hospital, Boston, MA) G Gabriel A. Brooks (Dartmouth Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH) D Don Steven Dizon (Tufts Medical Center, Boston, MA) H Hannah W. Hazard-Jenkins (WVU Cancer Institute, West Virginia University, Morgantown, WV) R Raymond U. Osarogiagbon (Multidisciplinary Thoracic Oncology Program Baptist Cancer Center Memphis Tennessee USA) S Sandra L. Wong (Emory University, Atlanta, GA) D Deb Schrag (Memorial Sloan Kettering Cancer Center, New York) M Michael J. Hassett (Dana-Farber Cancer Institute, Boston, MA)

Abstract

e23277 Background: Postoperative PROs reflect patients’ subjective experiences and are influenced by numerous factors, including disease severity, surgery type and complexity, duration of hospitalization, and perioperative support. By measuring variation in postoperative PROs after cancer surgery, we sought to gain insight into potentially modifiable factors at the patient, surgeon and surgical center levels that might inform interventions to improve outcomes. Methods: We studied patients who had colectomy, hysterectomy, lobectomy, or pancreaticoduodenectomy at 6 centers participating in the SIMPRO study who completed ≥1 ePRO survey. For each surgical procedure, we fit a multilevel mixed-effects regression model with random effects for patient, surgeon, and center to partition the variance in total symptom scores. The total symptom score is the summation of 12 frequently reported postoperative symptoms (range 0-34), with higher scores indicating greater symptom burden. The fixed-effects covariates in the model included patient age, sex, race, ethnicity, comorbidities, primary language, poverty, insurance, marital status and time since surgical discharge. Coefficients were estimated for fixed effects. Intraclass correlation coefficients (ICCs) were calculated from the estimated variance components to quantify the proportion of variance attributable to patients, surgeons and centers (Table). Results: A total of 3808 patients had surgery (1316 hysterectomy, 1072 colectomy, 590 lobectomy, 198 pancreaticoduodenectomy) performed by 35, 52, 23, and 13 surgeons respectively across 6 centers. Most variation in PROs was attributable to patients (75% to 78%). The proportion of variation attributable to surgeons and centers was below 3% for hysterectomy, colectomy and lobectomy. Unexplained variation was less than 26% across procedures. Conclusions: Across surgeries for four common cancers, most variation in postoperative symptoms occurred at the patient level. The unexplained (residual) variation could be due to cancer stage, postoperative complications, supportive care programs, or unmeasured confounders. Identifying and incorporating potentially modifiable factors may enable targeted interventions to reduce the postoperative symptom burden. Clinical trial information: NCT03850912 . Decomposition of variance in postoperative PROs: intraclass correlation coefficients attributable to patients, surgeons, and centers ( ICC, %) . Hysterectomy Colectomy Lobectomy Pancreaticoduodenectomy Patients 75.00% 77.67% 76.10% 77.75% Surgeons 1.90% 0.55% 2.40% Center 1.10% 1.21% 2.00% Unexplained 22.00% 20.57% 19.50% 22.25%

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (12)

R

Roshan Paudel

Dana-Farber Cancer Institute, Boston, MA

H

Hajime Uno

C

Christine M. Cronin

Dana-Farber Cancer Institute, Boston, MA

J

Jessica J. Bian

Maine Medical Center, Portland, ME

E

Eleonore Kugener

Brigham and Women's Hospital, Boston, MA

G

Gabriel A. Brooks

Dartmouth Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH

D

Don Steven Dizon

Tufts Medical Center, Boston, MA

H

Hannah W. Hazard-Jenkins

WVU Cancer Institute, West Virginia University, Morgantown, WV

R

Raymond U. Osarogiagbon

Multidisciplinary Thoracic Oncology Program Baptist Cancer Center Memphis Tennessee USA

S

Sandra L. Wong

Emory University, Atlanta, GA

D

Deb Schrag

Memorial Sloan Kettering Cancer Center, New York

M

Michael J. Hassett

Dana-Farber Cancer Institute, Boston, MA